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Alcohol and Medication
Interactions
Ron Weathermon, Pharm.D., and David W. Crabb, M.D.
Many medications can interact with alcohol, thereby altering the metabolism or effects of
alcohol and/or the medication. Some of these interactions can occur even at moderate
drinking levels and result in adverse health effects for the drinker. Two types of alcohol-
medication interactions exist: (1) pharmacokinetic interactions, in which alcohol interferes
with the metabolism of the medication, and (2) pharmacodynamic interactions, in which
alcohol enhances the effects of the medication, particularly in the central nervous system
(e.g., sedation). Pharmacokinetic interactions generally occur in the liver, where both alcohol
and many medications are metabolized, frequently by the same enzymes. Numerous classes
of prescription medications can interact with alcohol, including antibiotics, antidepressants,
antihistamines, barbiturates, benzodiazepines, histamine H2 receptor antagonists, muscle
relaxants, nonnarcotic pain medications and anti-inflammatory agents, opioids, and warfarin.
In addition, many over-the-counter and herbal medications can cause negative effects when
taken with alcohol. KEY WORDS: moderate AOD use; prescription drug; adverse drug
interaction; drug metabolism; ethanol metabolism; cytochromes; liver; alcohol
dehydrogenases; antibiotics; antidepressants; histamine H1 receptor blockaders; barbiturates;
benzodiazepines; histamine H2 receptor blockaders; anti-inflammatory agents; opioids;
warfarin; over-the-counter drug; literature review
Most people who consumealcohol, whether in moderateor large quantities, also take
medications, at least occasionally. As a
result, many people ingest alcohol
while a medication is present in their
body or vice versa. A large number of
medications—both those available
only by prescription and those avail-
able over the counter (OTC)—have
the potential to interact with alcohol.
Those interactions can alter the meta-
bolism or activity of the medication
and/or alcohol metabolism, resulting
in potentially serious medical 
consequences. For example, the 
sedative effects of both alcohol and
sedative medications can enhance
each other (i.e., the effects are addi-
tive), thereby seriously impairing a
person’s ability to drive or operate
other types of machinery. 
Most studies assessing alcohol-
medication interactions focus on the
effects of chronic heavy drinking.
Relatively limited information is avail-
able, however, on medication interac-
tions resulting from moderate alcohol
consumption (i.e., one or two standard
drinks1 per day). Researchers, physi-
cians, and pharmacists must therefore
infer potential medication interactions
at moderate drinking levels based on
observations made with heavy drinkers.
In addition, moderate alcohol consump-
tion may directly influence some of
the disease states for which medications
are taken (see sidebar, pp. 52–53, for
further discussion of alcohol’s influ-
ences on various disease states). This
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equivalent to approximately 0.5 ounce, or 12
grams (g), of pure alcohol.
article discusses alcohol absorption,
distribution, and metabolism within
the body; the sites where potential
alcohol-medication interactions can
occur; and possible adverse effects
from various alcohol-medication
combinations, including OTC or
herbal products. 
Alcohol Absorption,
Distribution, and
Metabolism
Gastrointestinal Absorption 
and Metabolism
When alcohol is ingested through the
mouth, a small amount is immediately
broken down (i.e., metabolized) in the
stomach. Most of the remaining alcohol
is then absorbed into the bloodstream
from the gastrointestinal tract, primar-
ily the stomach and the upper small
intestine. Alcohol absorption occurs
slowly from the stomach but rapidly
from the upper small intestine. Once
absorbed, the alcohol is transported to
the liver through the portal vein. A
portion of the ingested alcohol is
metabolized during its initial passage
through the liver; the remainder of
the ingested alcohol leaves the liver,
enters the general (i.e., systemic) cir-
culation, and is distributed through-
out the body’s tissues. 
Alcohol metabolism (or the meta-
bolism of any other substance) that
occurs in the gastrointestinal tract and
during the substance’s initial passage
through the liver is called “first-pass
metabolism” (see figure 1). For exam-
ple, the mucosa lining the stomach
contains enzymes that can metabolize
alcohol as well as other substances;
some of those enzymes, including
alcohol dehydrogenase (ADH) and
cytochrome P450 are described in
more detail in the section “Alcohol
Metabolism in the Liver.” 
The contribution of stomach (i.e.,
gastric) enzymes to first-pass alcohol
metabolism, however, is controversial.
Whereas some researchers have pro-
posed that gastric enzymes play a major
role in first-pass metabolism (Lim et
al. 1993), other investigators consider
the liver to be the primary site of first-
pass metabolism (Levitt and Levitt
1998). Furthermore, some gender dif-
ferences appear to exist in the overall
extent of, and in the contribution of,
gastric enzymes to first-pass meta-
bolism. For example, the extent of
first-pass metabolism is less in women
than in men and some studies also
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Figure 1 Schematic representation of first-pass metabolism. (A) Alcohol ingested through the mouth reaches the stomach, where
a portion is metabolized by the enzyme alcohol dehydrogenase (ADH). The remaining alcohol enters the intestine, where
most of the remainder is absorbed into the bloodstream and enters the portal vein that leads to the liver. In the liver, part
of the alcohol is metabolized by ADH or cytochrome P450. The remaining alcohol enters the general (i.e., systemic)
circulation and eventually is transported back to the liver and metabolized there. The metabolism of alcohol in the stomach
or during the first passage through the liver after absorption from the intestine is called first-pass metabolism. (B) Changes
in blood alcohol levels (BALs) after oral alcohol ingestion and after intravenous administration of the same alcohol dose.
The difference in BALs achieved with both administration routes (i.e., the amount by which the BAL is lower after oral
ingestion) represents that portion of the ingested alcohol that has been broken down by first-pass metabolism before
reaching the systemic circulation. 
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have found lower gastric ADH activity
in women (Thomasson 1995). 
First-pass metabolism is readily
detectable after consumption of low
alcohol doses2 that leave the stomach
slowly (e.g., because they have been
consumed with a meal). Thus, under
such conditions of delayed gastric emp-
tying, more alcohol can be metabolized
in the stomach or absorbed slowly
from the stomach and transported to
the liver for first-pass metabolism. 
In general, probably only a small frac-
tion (perhaps 10 percent) of ingested
alcohol is eliminated from the body
by first-pass metabolism after consump-
tion of low doses of alcohol. As alcohol
ingestion increases, the amount of alco-
hol eliminated by first-pass metabolism
becomes an even smaller fraction of
the total amount of alcohol consumed.
Some researchers have suggested, how-
ever, that some medications can block
first-pass metabolism, resulting in
blood alcohol levels (BALs) that are
higher than normal for a given alcohol
dose. For example, people taking med-
ications that can inhibit ADH activity—
such as aspirin and certain medications
used to treat ulcers and heartburn (i.e.,
H2 receptor antagonists, such as cime-
tidine [Tagamet®], nizatidine [Axid®]
and ranitidine [Zantac®])—experience
reduced first-pass metabolism (Caballaria
et al. 1991; Roine et al. 1990). Similarly,
medications that accelerate gastric
emptying (e.g., the stomach medica-
tions metoclopramide [Reglan®] and
cisapride [Propulsid®] and the antibi-
otic erythromycin) may reduce first-
pass metabolism in the stomach.
The contribution of bacteria living
in the large intestine (i.e., colon) to
gastrointestinal alcohol metabolism is
still controversial. Laboratory experi-
ments have demonstrated that these
bacteria can metabolize alcohol. In
addition, a breakdown product of alco-
hol (i.e., acetaldehyde) is generated in
the colon after alcohol administration.
Finally, studies in rats found that ani-
mals treated with an antibiotic to reduce
the number of bacteria in the colon
showed a reduced alcohol elimination
rate compared with untreated rats
(Nosova et al. 1999). If these research
findings also apply to humans, alco-
hol elimination may be delayed in
people taking certain antibiotics that
are active against colonic bacteria. 
Alcohol’s Distribution in the Body
Alcohol that has not been eliminated
by first-pass metabolism enters the
systemic circulation and is distributed
throughout the body water (i.e., the
blood and the watery fluid surround-
ing and inside the cells). Alcohol does
not dissolve in fat tissues. The propor-
tion of body water and body fat differs
between men and women and between
young and old people; women and
older people generally have more body
fat and less body water than do men
and younger people. As a result, alco-
hol distribution throughout the body
depends on a person’s gender and age. 
Differences in alcohol distribution
patterns also affect the BALs achieved
with a given alcohol dose (Thomasson
1995). Thus, women, whose lower body
water creates a smaller fluid volume in
which the alcohol is distributed, tend
to achieve higher BALs than do men
after consuming the same amount of
alcohol. The normal loss of lean body
weight and increase in body fat that
occurs with aging has a similar effect
on BALs. The potentially higher BALs
can exaggerate alcohol-medication
interactions in both women and older
people. Aside from this effect of gender
and age on BALs, researchers have not
reported any other major gender- or
age-related differences in susceptibility
to alcohol-medication interactions.
However, this issue still requires fur-
ther investigation.
Alcohol Metabolism in the Liver
The liver is the primary site of alcohol
metabolism. Alcohol circulating in the
blood is transported to the liver, where
it is broken down by several enzymes,
the most important of which are ADH
and cytochrome P450 (figure 2). The
activities of these enzymes may vary
from person to person, contributing
to the observed variations in alcohol
elimination rates among individuals
(Martin et al. 1985).
ADH converts alcohol into acetal-
dehyde in a reaction called oxidation.
Acetaldehyde, which is a toxic sub-
stance that may contribute to many 
of alcohol’s adverse effects, is broken
down further by an enzyme called
2Low alcohol doses are defined here as 0.3 g per
kilogram body weight, equivalent to approximately
two standard drinks for a person weighing 70 kg.
Figure 2 Alcohol metabolism in the liver. Alcohol is broken down to acetaldehyde
either by alcohol dehydrogenase (ADH) or cytochrome P450 (CYP). The
acetaldehyde then is broken down to acetic acid and water by two variants
of the enzyme aldehyde dehydrogenase (ALDH). Alcohol metabolism by
ADH generates a byproduct called reduced nicotinamide adenine dinu-
cleotide (NADH). Excessive NADH levels can inhibit glucose production
(i.e., gluconeogenesis) and breakdown (i.e., oxidation) of fat molecules as
well as stimulate production of fat molecules.
NAD+
ADH
NADH
Alcohol Acetaldehyde
CYPs
ALDH2
ALDH1
Acetate
Inhibition of gluconeogenesis
Inhibition of fat oxidation
Stimulation of fat synthesis
aldehyde dehydrogenase (ALDH).
(The function of ALDH is discussed
in more detail in the following sec-
tion.) Several ADH variants (i.e.,
isozymes) exist, which differ in their
activity when studied in the labora-
tory. In humans, however, the effect
of different ADH isozymes on alcohol
elimination is small (Thomasson 1995).
Although different ADH variants are
associated with different risks of devel-
oping alcoholism, no studies to date
have researched the effects of these
isozymes on a person’s susceptibility to
alcohol-medication interactions.
In contrast to ADH, the alcohol-
metabolizing enzyme cytochrome
P450—also called microsomal
ethanol oxidizing system (MEOS)
(Lieber 1994)—plays a central role 
in alcohol-medication interactions.
Cytochrome P450 actually is a system
consisting of two enzymes, one called
cytochrome P450 reductase and
another one called CYP2E1, which
are both embedded in the membrane
of a cell component called the endoplas-
mic reticulum.3 In addition to alcohol,
CYP2E1 can metabolize numerous
compounds, including acetaldehyde, the
pain medication acetaminophen, the
antibiotic isoniazid, and the barbiturate
phenobarbital. Accordingly, CYP2E1
plays an important role in many alco-
hol-medication interactions. 
In people consuming alcohol only
occasionally, CYP2E1 metabolizes
only a small fraction of the ingested
alcohol. Chronic heavy drinking,
however, can increase CYP2E1 activ-
ity up to tenfold, resulting in a sub-
stantial increase in the proportion of
alcohol that is metabolized by this
enzyme rather than by ADH (figure
3) (Lieber 1994). The effect of lower
levels of alcohol consumption on
CYP2E1 activity is unknown. Because
CYP2E1 also metabolizes several medi-
cations, alcoholics, in whom CYP2E1
activity is enhanced, exhibit increased
metabolic rates for those medications
when they are sober. When those
alcoholics are intoxicated, however,
the alcohol in their system competes
with the medication for metabolism
by CYP2E1. As a result, the break-
down of the medication is slowed.
With many medications, increased 
or decreased metabolic rates can have
adverse or even fatal consequences.
With increased metabolic rates, the
medication’s concentration in the
body may be too low or may decline
too fast for it to be effective. Con-
versely, decreased metabolic rates 
may result in the accumulation of
higher drug concentrations over
longer periods of times, which may
result in harmful overdoses.
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(A) In the absence of alcohol, CYP activity is relatively
low. CYP breaks down the medication, and the
resulting products (i.e., metabolites) are excreted. 
(B) After moderate alcohol consumption, CYP metabo-
lizes alcohol in addition to the medication. As a
result of competition for CYP between alcohol and
the medication, the medication’s metabolism is
reduced, and the production of metabolites as well
as their excretion declines, resulting in higher medi-
cation levels in the body. In addition, interactions
between alcohol and the medication may occur in
the central nervous system (CNS).
(C) In chronic heavy drinkers who are sober, CYP activity
is enhanced. As a result, the breakdown of medications
metabolized by CYP increases, and metabolite
levels as well as their excretion are elevated, possibly
resulting in insufficient medication levels in the body.
Furthermore, toxic metabolites may accumulate.
(D) In chronic heavy drinkers who are intoxicated, CYP is
activated, but most of the enzyme is involved in alcohol
metabolism. Consequently, the CYP-dependent
metabolism of other medications is reduced, and
metabolite levels and their excretion decline. Alcohol-
medication interactions also can occur in the CNS.
Figure 3 Potential alcohol-medication interactions involving cytochrome P450 enzymes (CYP) in the liver.
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3The endoplasmic reticulum is an extensive net-
work of membrane-enclosed tubules within the
cell that is involved in the production of proteins
and fat molecules and in the transport of those
molecules within the cell.
Wide variation exists among people
in both CYP2E1 activity and metabolic
rates for medications broken down by
this enzyme (e.g., acetaminophen and
chlorzoxasone, a medication used to
relieve muscle pain). Some of this vari-
ation may be genetically determined,
although the specific underlying mecha-
nism is unknown (Carriere et al.
1996). A person’s CYP2E1 activity
level, however, could influence his or
her susceptibility to alcohol-medication
interactions involving this enzyme. For
example, in a person with innately low
metabolic rates, a further decrease in
metabolism when alcohol is consumed
would affect medication levels (and
thus the potential for adverse effects
or interactions with alcohol) to a greater
extent than in a person with innately
high metabolic rates.
In addition to CYP2E1, at least
two other cytochrome enzymes that
metabolize various medications (i.e.,
CYP3A4 and CYP1A2) also can
break down alcohol (Salmela et al.
1998). Moreover, the amounts of var-
ious enyzmes of the cytochrome
CYP3A family (including CYP3A4)
can increase from alcohol consump-
tion (Niemela et al. 1998). Thus,
potential interactions also exist
between alcohol and medications
metabolized by these cytochromes.
Acetaldehyde Metabolism in the Liver
As mentioned in the previous section,
alcohol breakdown by ADH generates
acetaldehyde, which, in turn, is metab-
olized further by ALDH. Two major
types of ALDH (i.e., ALDH1 and
ALDH2) exist, which are located in
different regions of the cell. ALDH1
requires relatively high acetaldehyde
concentrations in the cell to be active,
whereas ALDH2 is active at extremely
low acetaldehyde levels. Accordingly,
ALDH2 may play a particularly impor-
tant role in acetaldehyde breakdown
after moderate alcohol consumption.
The significance of ALDH2 activity
in alcohol and acetaldehyde metabolism
is further supported by an inborn
variation in alcohol metabolism that
occurs primarily in people of Asian
heritage but which is rare among
Caucasians. After consuming alcohol,
many Asian people experience an
unpleasant “flushing” reaction that
can include facial flushing, nausea,
and vomiting. These symptoms are
caused by acetaldehyde accumulation
in the body. Thus, following alcohol
consumption, acetaldehyde levels in
people susceptible to the flushing
reaction may be 10 to 20 times higher
than in people who do not experience
flushing. Researchers have noted that
approximately 40 percent of Asians
lack ALDH2 activity because they
have inherited one or two copies of 
an inactive variant of the gene that
produces ALDH2 (Goedde et al.
1989). Most of these individuals flush
when they consume alcohol. These
observations imply that ALDH2 
plays a crucial role in maintaining low
acetaldehyde levels during alcohol
metabolism. Consequently, even inad-
vertent alcohol administration to peo-
ple of Asian heritage (who may have
inherited an inactive ALDH2 gene)
can cause unpleasant reactions. Thus,
the potential flushing response should
be an important concern for physi-
cians and patients, because many 
prescription and OTC medications
contain substantial amounts of alco-
hol (see table 1). Physicians and phar-
macists therefore must be alert to the
possibility that Asian patients may be
intolerant of these medications.
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Table 1 Alcohol Content of Prescription and Over-the-Counter Medications 
Product Alcohol Content (%)
Betadine (mouthwash, gargle) 8.8
Cepacol (mouthwash, gargle) 14.0
Cheracol Sore Throat 12.5
Chlortrimeton syrup 7.0
Cimetidine Oral Solution 2.8
Cyclosporine Oral Solution 9.5–12.5
Cyproheptadine 5.0
DentSure (denture rinse, peppermint) 14.4
Dr. Tichenor’s Antiseptic 70*
Digoxin Elixir 10.0
Entex 5.0
Furosemide Liquid 11.5
Intensol (diazepam) 19.0
Listerine 26.9
Listerine Cool Mint or Freshburst 21.6
Lomotil Liquid 15.0
Mellaril/Thioridiazine 3.0–4.2
Mentadent Mouthwash 10.0
Oral-B Anti-Plaque Rinse 8.0
Plax-Advanced Formula 8.7
Peri-colace 10.0
Phenobarbital Elixir 14.0
Promethazine/Phenergan 7.0
Ranitidine 7.5
Scope, Baking Soda 9.9
Scope, Cool Peppermint 14.0
Senokot Syrup 7.0
Targon Smokers’ Mouth Wash, Clean Taste 15.6*
Targon Smokers’ Mouth Wash, Original 16.0*
Tavist Oral Solution 5.5
Theophylline Elixir 20.0
Viadent Oral Rinse 10.0
*Specifically denatured alcohol (SDA) 38B content.
SOURCE: Knodel, L.C., ed. Nonprescription Products: Formulations and Features. 1998–1999. Washington,
DC: American Pharmaceutical Association, 1999.
Several medications can inhibit even
active ALDH molecules (both ALDH1
and ALDH2), thereby inducing a flush-
ing reaction in all people who consume
alcohol after taking those medications.
In fact, this medication effect is
exploited in alcoholism treatment. The
medication disulfiram (Antabuse®),
which inhibits mainly ALDH1 but also
ALDH2, is given to alcoholics trying
to quit drinking. If the alcoholic drinks
alcohol after taking disulfiram, he or she
will experience a severe flushing reaction.
The experience of such an unpleasant
reaction, or even the expectation that
this reaction will occur if alcohol is con-
sumed, can help many alcoholics achieve
and maintain abstinence. Moderate
drinkers are not likely to be treated
with disulfiram; however, many other
medications (and certain toxic sub-
stances) also can induce disulfiram-like
reactions when combined with alcohol
(see table 2). For example, the com-
monly prescribed diabetes medication
chlorpropamide and the antibiotics
cefotetan and metronidazole can induce
disulfiram-like reactions, even after inges-
tion of only small alcohol amounts.
These reactions not only are unpleasant
but also can result in serious medical
consequences. For example, flushing is
associated with a widening (i.e., dilation)
of the blood vessels, low blood pressure,
and rapid heartbeat, all of which can
be dangerous in patients with coronary
artery disease. Patients taking medica-
tions that can induce disulfiram-like
reactions therefore should be advised
not to drink alcohol. 
Alcohol’s Effects on Liver Metabolism 
In addition to influencing the meta-
bolism of many medications by acti-
vating cytochrome P450 enzymes in
the liver, alcohol and its metabolism
cause other changes in the liver’s ability
to eliminate various substances from
the body. Thus, alcohol metabolism
affects the liver’s redox state and glu-
tathione levels. The term “redox state”
refers to the concentrations of two
substances in the cells—nicotinamide
adenine dinucleotide (NAD+) and
reduced NAD+ (NADH)—that are
needed for the functioning of many
enzymes. Alcohol metabolism by ADH
results in the conversion of NAD+
into NADH, thereby increasing the
liver’s NADH levels (see figure 2).
Elevated NADH levels, in turn, stim-
ulate the generation of fat molecules
and interfere with the ability of other
liver enzymes to break down fat mole-
cules and produce the sugar glucose.
Through these metabolic changes,
alcohol metabolism can substantially
affect the body’s general metabolism
and functioning. Furthermore, elevated
NADH levels may prevent the liver
from generating UDP-glucuronic acid,
a substance that must be attached to
various medications before they can be
excreted from the body.
Glutathione is an antioxidant, an
agent that prevents certain highly reac-
tive, oxygen-containing molecules (i.e.,
reactive oxygen species) from damag-
ing the cells. Both alcohol metabolism
and the metabolism of certain medi-
cations can generate reactive oxygen
species, thereby inducing a state called
oxidative stress in the cells. At the same
time, heavy alcohol consumption
reduces the amount of glutathione in
liver cells, particularly in the mitochon-
dria (i.e., the cell components where
most of the cell’s energy is generated).
Consequently, the cell’s protective
mechanisms against oxidative stress are
impaired, and cell death may result.
Furthermore, reduced glutathione 
levels increase the liver’s susceptibility
to damage caused by toxic breakdown
products of some medications (e.g.,
acetaminophen and isoniazid). 
Common Alcohol-
Medication Interactions
Mechanisms of Alcohol-Medication
Interactions 
Interactions between alcohol and a med-
ication can occur in a variety of situa-
tions that differ based on the timing
of alcohol and medication consump-
tion. For example, such interactions
can occur in people who consume alco-
hol with a meal shortly before or after
taking a medication or who take pain
medications after drinking to prevent
a hangover. Alcohol-medication inter-
actions fall into two general categories:
pharmacokinetic and pharmacodynamic.
Pharmacokinetic interactions are those
in which the presence of alcohol directly
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Table 2 Commonly Used Medications That Cause Disulfiram-Like Reactions (i.e.,
Flushing, Nausea, Vomiting, Sweating) After Alcohol Consumption
Type of Medication Generic Names Brand Names
Analgesics (NSAIDs) Phenacetin various
Phenylbutazone
Antibiotics Cefamandole Mandol
Cefoperazone Cefobid
Cefotetan Cefotan
Chloramphenicol various
Griseofulvin Fulvicin, Grifulvin,Grisactin
Isoniazid Nydrazid, Rifamate, Rifater
Metronidazole Flagyl
Nitrofurantoin Furadantin, Macrodantin
Sulfamethoxazole Bactrim, Septra
Sulfisoxazole Pediazole
Cardiovascular medications Isosorbide dinitrate Dilatrate, Isordil, Sorbitrate
(nitrates) Nitroglycerin Nitro-Bid, Nitrostat
Diabetes medications Chlorpropamide Diabinese
(sulfonylureas) Glyburide DiaBeta, Glynase, Micronase
Tolazamide generic
Tolbutamide generic
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Table 3 Interactions Between Alcohol and Various Classes of Medications
Drug Class 
(Conditions 
for which they 
are used) Generic Name Brand Name Availability Type of Interaction
Analgesics Aspirin various Rx and OTC •Aspirin increases gastric emptying, leading to
(pain relief) Acetaminophen e.g., Tylenol faster alcohol absorption in the small intestine; 
may also inhibit gastric ADH.
•Alcohol enhances acetaminophen metabolism into
a toxic product, potentially causing liver damage.
Antibiotics Erythromycin various Rx •Erythromycin may increase gastric emptying,
(microbial infections) Isoniazid Nydrazid, leading to faster alcohol absorption in the 
Rifamate, Rifater small intestine.
•Alcohol increases the risk of isoniazid-related
liver disease.
Anticonvulsants Phenytoin Dilantin Rx •Chronic alcohol consumption induces 
(seizure disorders) phenytoin breakdown.
Antihistamines Diphenhydramine e.g., Benadryl Rx and OTC •Alcohol enhances the effects of these agents
(allergies, colds) Chlorpheniramine various on the central nervous system (CNS), such as 
Clemastine drowsiness, sedation, and decreased motor skills.
Hydroxyzine Atarax, Vistaril •The interactions are more pronounced in 
Promethazine Phenergan elderly people.
Cyproheptadine Periactin •No documented interactions exist with 
nonsedating antihistamines (i.e., certrizine, 
hismanal, loratidine).
Anticoagulants Warfarin Coumadin Rx •Acute alcohol intake may increase anticoagulation
(prevention of blood clots) by decreasing warfarin metabolism; chronic 
alcohol ingestion decreases anticoagulation by 
increasing warfarin metabolism.
Antidiabetic agents Chlorpropamide Diabinese Rx •Alcohol consumption by diabetic patients taking
(blood sugar Glipizide Glucotrol these medications increases the risk of lower-
regulation) Glyburide DiaBeta, Glynase, than-normal blood sugar levels (i.e., hypoglycemia).
Micronase •Chlorpropamide, glyburide, and tolbutamide can 
Tolbutamide Orinase cause disulfiram-like interactions after alcohol 
Metformin Glucophage ingestion.
•Metformin may cause increased levels of lactic 
acid in the blood after alcohol consumption.
Barbiturates Phenobarbital various Rx •Chronic alcohol intake increases barbiturate
(anesthesia, pain relief) metabolism by cytochrome P450.
•Alcohol enhances the sedative and hypnotic
effects on the CNS.
Benzodiazepines Alprazolam Xanax Rx •Alcohol enhances the effects of these agents
(sedative agents) Chlordiazepoxide Librium on the CNS, such as drowsiness, sedation, and
Clonazepam Klonopin decreased motor skills.
Clorazepate Tranxene
Diazepam Valium
Lorazepam Ativan
Midazolam Versed
Oxazepam Serax
Temazepam Restoril
Triazolam Halcion
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Drug Class 
(Conditions 
for which they 
are used) Generic Name Brand Name Availability Type of Interaction
Histamine H2 Cimetidine Tagamet Rx and OTC •The agents inhibit ADH in the stomach, thereby 
receptor antagonists Nizatidine Axid reducing alcohol first-pass metabolism (see 
(ulcers, heart burn) Ranitidine Zantac figure 1), as well as increase gastric emptying. 
As a result, BALs are higher than expected
for a given alcohol dose; this effect increases
over time.
Immune modulators Methotrexate Rheumatrex Rx •Immune modulators (i.e., medications that affect 
(rheumatoid arthritis) immune cell function) are associated with a 
risk of liver damage, which is increased in
combination with alcohol.
Muscle relaxants Carisoprodol Soma Rx •Alcohol consumption enhances impairment
Cyclobenzaprine Flexeril of physical abilities (e.g., driving) and 
increases sedation.
•Carisoprodol produces an opiate-like high 
when taken with alcohol; it is metabolized to 
meprobamate and sometimes abused as a 
street drug. 
NSAIDs Ibuprofen e.g., Motrin Rx and OTC •Alcohol consumption increases the 
(pain relief and Flurbiprofen various associated risk of gastrointestinal bleeding.
inflammation) Fenoprofen Nalfon
Ketoprofen Orudis
Naproxen Naprosyn
Diclofenac Voltaren
Opioids (pain relief) Codeine various Rx •Alcohol enhances the effects of these 
Hydromorphone Dilaudid agents on the CNS, such as drowsiness,
Fentanyl generic sedation, and decreased motor skills.
Morphine various
Meperidine e.g., Demerol
Propoxyphene Darvon, Wygesic
Sedatives and Chloral hydrate Noctec Rx •Alcohol inhibits the metabolism of these 
hypnotics Meprobamate Equanil, Miltown agents and produces a depressant effect
on the CNS that includes sleepiness,
disorientation, incoherence, and confusion.
Tricyclic Amitriptyline Elavil, Endep Rx •Alcohol consumption increases the risk of 
antidepressants Clomipramine Anafranil sedation and a sudden drop in blood 
(depression) Desipramine Norpramin pressure when a person stands up (i.e., 
Doxepin Adapin, Sinequan orthostatic hypotension).
Imipramine Tofranil
Nortriptyline Aventyl, Pamelor
Trimipramine Surmontil
Herbal medications Chamomile various OTC •Alcohol may accentuate the drowsiness that
(sleep aids) Echinacea preparations is associated with these herbal preparations.
Valerian 
ADH = alcohol dehydrogenase; BAL = blood alcohol level; NSAIDs = nonsteroidal anti-inflammatory drugs; OTC = over the counter; Rx = prescription. 
interferes with the normal metabolism
of the medication. This interference
can take two forms, as follows:
• The breakdown and excretion of
the affected medications are
delayed, because the medications
must compete with alcohol for
breakdown by cytochrome P450.
This type of interaction has been
described mostly for metabolic
reactions involving CYP2E1, but it
also may involve CYP3A4 and
CYP1A2 (Salmela et al. 1998).
• The metabolism of the affected
medications is accelerated, because
alcohol enhances the activity of
medication-metabolizing cyto-
chromes. When alcohol is not pre-
sent simultaneously to compete for
the cytochromes, increased cyto-
chrome activity results in an increased
elimination rate for medications that
these enzymes metabolize. 
Pharmacodynamic alcohol-medication
interactions do not involve enzyme
inhibition or activation, but rather
refer to the additive effects of alcohol
and certain medications. In this type
of interaction, which occurs most
commonly in the central nervous sys-
tem (CNS), alcohol alters the effects
of the medication without changing
the medication’s concentration in the
blood. With some medications (e.g.,
barbiturates and sedative medications
called benzodiazepines), alcohol acts
on the same molecules inside or on
the surface of the cell as does the med-
ication. These interactions may be
synergistic—that is, the effects of the
combined medications exceed the sum
of the effects of the individual medica-
tions. With other medications (e.g.,
antihistamines and antidepressants)
alcohol enhances the sedative effects
of those medications but acts through
different mechanisms from those agents.
Specific Alcohol-Medication
Interactions
This section describes different classes
of medications and their interactions
with alcohol (see table 3). The poten-
tial for the occurrence and relevance
of alcohol-medication interactions in
moderate drinkers may differ, however,
between pharmacokinetic and pharma-
codynamic interactions. The number
of potential pharmacokinetic interac-
tions with alcohol is great, because the
various cytochrome P450 enzymes meta-
bolize many medications.4 However,
many of the pharmacokinetic interac-
tions discussed here were first discov-
ered in heavy drinkers or alcoholics or
were studied in animals given large
alcohol doses in their diet. Although
the potential for such effects certainly
exists even after low alcohol consump-
tion, researchers have not yet demon-
strated the occurrence and relevance
of those effects in moderate drinkers.
Conversely, pharmacodynamic inter-
actions can occur with intermittent
alcohol consumption and even after a
single episode of drinking. Accordingly,
those interactions clearly pertain to
moderate drinkers. 
Antibiotics. The package inserts for
most antibiotics include a warning for
patients to avoid using alcohol with
those medications. The rationale for
these warnings is not entirely clear,
however, because only a few antibi-
otics appear to interact with alcohol.
For example, although some antibi-
otics induce flushing, most antibiotics
do not. The antibiotic erythromycin
may increase alcohol absorption in
the intestine (and, consequently,
increase BALs) by accelerating gastric
emptying. Furthermore, people tak-
ing the antituberculosis drug isoniazid
should abstain from alcohol, because
isoniazid can cause liver damage,
which may be exacerbated by daily
alcohol consumption. Aside from
these effects, however, moderate alco-
hol consumption probably does not
interfere with antibiotic effectiveness.
Possibly, concerns regarding the con-
current use of alcohol and antibiotics
grew from research findings indicat-
ing that heavy alcohol use can impair
the function of certain immune cells
and that alcoholics are predisposed to
certain infections. These effects, how-
ever, are unlikely to occur in moder-
ate drinkers.
Antidepressants. Several classes of
antidepressant medications exist,
including tricyclic antidepressants
(TCAs), selective serotonin reuptake
inhibitors (SSRIs), monoamine oxi-
dase (MAO) inhibitors, and atypical
antidepressants. These classes differ in
their mechanism of action in that
they affect different brain chemicals.
All types of antidepressants, however,
have some sedative as well as some
stimulating activity. 
TCAs with a higher ratio of sedative-
to-stimulant activity (i.e., amitripty-
line, doxepin, maprotiline, and
trimipramine) will cause the most
sedation. Alcohol increases the TCAs’
sedative effects through pharmacody-
namic interactions. In addition, alcohol
consumption can cause pharmacokinetic
interactions with TCAs. For example,
alcohol appears to interfere with the
first-pass metabolism of amitriptyline
in the liver, resulting in increased ami-
triptyline levels in the blood. In addi-
tion, alcohol-induced liver disease
further impairs amitriptyline break-
down and causes significantly increased
levels of active medication in the body
(i.e., increased bioavailability). High
TCA levels, in turn, can lead to convul-
sions and disturbances in heart rhythm. 
SSRIs (i.e., fluvoxamine, fluoxetine,
paroxetine, and sertraline), which are
currently the most widely used anti-
depressants, are much less sedating
than are TCAs. In addition, no serious
interactions appear to occur when
these agents are consumed with mod-
erate alcohol doses (Matilla 1990). In
fact, SSRIs have the best safety profile
of all antidepressants, even when com-
bined in large quantities with alcohol
(e.g., in suicide and overdose situations).
Conversely, people taking MAO
inhibitors or atypical antidepressants
can experience adverse consequences
when simultaneously consuming alco-
hol. Thus, MAO inhibitors (e.g.,
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4An Internet Web site (www.accp.com/p450.html)
catalogs the classes of cytochrome P450 molecules
that can metabolize various medications. This
resource can help identify medications metabo-
lized by CYP2E1 that may potentially interact
with alcohol.
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phenelzine and tranylcypromine) can
induce severe high blood pressure if
they are consumed together with a
substance called tyramine, which is
present in red wine. Accordingly, peo-
ple taking MAO inhibitors should be
warned against drinking red wine. The
atypical antidepressants (i.e., nefazodone
and trazodone) may cause enhanced
sedation when used with alcohol. 
Antihistamines. These medications,
which are available both by prescription
and OTC, are used in the management
of allergies and colds. Antihistamines
may cause drowsiness, sedation, and
low blood pressure (i.e., hypotension),
especially in elderly patients (Dufour
et al. 1992). Through pharmacody-
namic interactions, alcohol can substan-
tially enhance the sedating effects of
these agents and may thereby increase,
for example, a person’s risk of falling
or impair his or her ability to drive or
operate other types of machinery. As a
result of these potential interactions,
warning labels on OTC antihistamines
caution patients about the possibility
of increased drowsiness when consum-
ing the medication with alcohol. Newer
antihistamines (i.e., certrizine and
loratidine) have been developed to
minimize drowsiness and sedation
while still providing effective allergy
relief. However, these newer medica-
tions may still be associated with an
increased risk of hypotension and falls
among the elderly, particularly when
combined with alcohol. Consequently,
patients taking nonsedating antihis-
tamines still should be warned against
using alcohol.
Barbiturates. These medications are
sedative or sleep-inducing (i.e., hyp-
notic) agents that are frequently used
for anesthesia. Phenobarbital, which
is probably the most commonly pre-
scribed barbiturate in modern prac-
tice, also is used in the treatment of
seizure disorders. Phenobarbital acti-
vates some of the same molecules in
the CNS as does alcohol, resulting in
pharmacodynamic interactions between
the two substances. Consequently,
alcohol consumption while taking
phenobarbital synergistically enhances
the medication’s sedative side effects.
Patients taking barbiturates therefore
should be warned not to perform tasks
that require alertness, such as driving or
operating heavy machinery, particularly
after simultaneous alcohol consumption.
In addition to the pharmacodynamic
interactions, pharmacokinetic interac-
tions between alcohol and phenobar-
bital exist, because alcohol inhibits the
medication’s breakdown in the liver.
This inhibition results in a slower meta-
bolism and, possibly, higher blood
levels of phenobarbital. Conversely,
barbiturates increase total cytochrome
P450 activity in the liver and accelerate
alcohol elimination from the blood
(Bode et al. 1979). This acceleration
of alcohol elimination probably does
not have any adverse effect. 
Benzodiazepines. Like barbiturates,
benzodiazepines (BZDs) are classified
as sedative-hypnotic agents and act
through the same brain molecules as do
barbiturates. Accordingly, as with bar-
biturates, concurrent consumption of
BZDs and moderate amounts of alcohol
can cause synergistic sedative effects,
leading to substantial CNS impairment.
It is worth noting that both barbitu-
rates and benzodiazepines can impair
memory, as can alcohol. Consequently,
the combination of these medications
with alcohol would exacerbate this
memory-impairing effect. In fact, this
effect sometimes is exploited by mix-
ing alcoholic beverages with BZDs,
such as the rapid-acting flunitrazepam
(Rohypnol®), an agent implicated in
date rape (Simmons and Cupp 1998).
In addition, the metabolism of certain
BZDs involves cytochrome P450,
leading to the alcohol-induced changes
in metabolism described earlier in 
this article.
Histamine H2 Receptor Antagonists
(H2RAs). As mentioned earlier in this
article, H2RAs (e.g., cimetidine, rani-
tidine, nizatidine, and famotidine),
which reduce gastric acid secretion,
are used in the treatment of ulcers
and heartburn. These agents reduce
ADH activity in the stomach mucosa
(Caballeria et al. 1991), and cimeti-
dine also may increase the rate of gas-
tric emptying. As a result, alcohol
consumed with cimetidine undergoes
less first-pass metabolism, resulting in
increased BALs. For example, in a
study of people who consumed three
or four standard drinks over 135 min-
utes while taking cimetidine, BALs
rose higher and remained elevated for
a longer period of time than in people
not taking cimetidine (Lieber 1997;
Gupta et al. 1995). Not all H2RAs,
however, exert the same effect on BALs
when taken with alcohol. Thus, cime-
tidine and ranitidine have the most
pronounced effect, nizatidine has an
intermediate effect, and famotidine
appears to have no effect (i.e., appears
not to interact with alcohol).5 In addi-
tion, because women generally appear
to have lower first-pass metabolism of
alcohol, they may be at less risk for
adverse interactions with H2RAs.
Muscle Relaxants. Several muscle relax-
ants (e.g., carisoprodol, cyclobenzaprine,
and baclofen), when taken with alcohol,
may produce a certain narcotic-like
reaction that includes extreme weakness,
dizziness, agitation, euphoria, and
confusion. For example, carisoprodol
is a commonly abused and readily
available prescription medication that
is sold as a street drug. Its metabolism
in the liver generates an anxiety-reducing
agent that was previously marketed as
5Another class of medications, which prevent gastric
acid production through a different mechanism
from the H2RAs (i.e., omeprazole and lansoprazole),
also do not appear to interact with alcohol.
Pharmacodynamic
interactions can
occur with
intermittent alcohol
consumption and
even after a single
episode of drinking.
a controlled substance (meprobamate).
The mixture of carisoprodol with beer
is popular among street abusers for
creating a quick state of euphoria.
Nonnarcotic Pain Medications 
and Anti-Inflammatory Agents. 
Many people frequently use nonnarcotic
pain medications and anti-inflamma-
tory agents (e.g., aspirin, acetaminophen,
or ibuprofen) for headaches and other
minor aches and pains. In addition,
arthritis and other disorders of the mus-
cles and bones are among the most
common problems for which older
people consult physicians (Adams 1995).
Nonsteroidal anti-inflammatory drugs
(NSAIDs) (e.g., ibuprofen, naproxen,
indomethacin, and diclofenac) and
aspirin are commonly prescribed or
recommended for the treatment of
these disorders and are purchased
OTC in huge amounts. Several poten-
tial interactions exist between alcohol
and these agents, as follows:
• NSAIDs have been implicated in
an increased risk of ulcers and gas-
trointestinal bleeding in elderly
people. Alcohol may exacerbate
that risk by enhancing the ability
of these medications to damage the
stomach mucosa (Adams 1995).6
• Aspirin, indomethacin, and ibupro-
fen cause prolonged bleeding by
inhibiting the function of certain
blood cells involved in blood clot
formation. This effect also appears
to be enhanced by concurrent alco-
hol use (Deykin et al. 1982).
• Aspirin has been shown to increase
BALs after small alcohol doses,
possibly by inhibiting first-pass
metabolism (Roine et al. 1990).
An important pharmacokinetic
interaction between alcohol and aceta-
minophen can increase the risk of
acetaminophen-related toxic effects
on the liver. Acetaminophen break-
down by CYP2E1 (and possibly
CYP3A) results in the formation of a
toxic product that can cause poten-
tially life-threatening liver damage. As
mentioned earlier, heavy alcohol use
enhances CYP2E1 activity. In turn,
enhanced CYP2E1 activity increases
the formation of the toxic acetamino-
phen product. To prevent liver damage,
patients generally should not exceed
the maximum doses recommended by
the manufacturers (i.e., 4 grams, or
up to eight extra-strength tablets of
acetaminophen per day). In people
who drink heavily or who are fasting
(which also increases CYP2E1 activ-
ity), however, liver injury may occur
at doses as low as 2 to 4 grams per
day. The specific drinking levels at
which acetaminophen toxicity is
enhanced are still unknown. Because
acetaminophen is easily available
OTC, however, labels on the packages
warn people about the potentially
dangerous alcohol-acetaminophen
combination. Furthermore, people
should be aware that combination
cough, cold, and flu medications may
contain aspirin, acetaminophen, or
ibuprofen, all of which might con-
tribute to serious health consequences
when combined with alcohol.
Opioids. Opioids are agents with
opium-like effects (e.g., sedation, pain
relief, and euphoria) that are used as
pain medications. Alcohol accentuates
the opioids’ sedating effects. Accord-
ingly, all patients receiving narcotic
prescriptions should be warned about
the drowsiness caused by these agents
and the additive effects of alcohol.
Overdoses of alcohol and opioids are
potentially lethal because they can
reduce the cough reflex and breathing
functions; as a result, the patients are
at risk of getting foods, fluids, or other
objects stuck in their airways or of
being unable to breathe.
Certain opioid pain medications
(e.g., codeine, propoxyphene, and 
oxycodone) are manufactured as 
combination products containing
acetaminophen. These combinations
can be particularly harmful when
combined with alcohol because they
provide “hidden” doses of acetamin-
ophen. As described in the previous
section, alcohol consumption may
result in the accumulation of toxic
breakdown products of acetamino-
phen. Therefore, patients using 
opioid-acetaminophen combination
products should be cautioned about
restricting the total amount of acetamin-
ophen they ingest daily (i.e., they
should not take regular acetaminophen
in addition to the combination product).
Warfarin. The anticoagulant warfarin
is used for the prevention of blood
clots in patients with irregular heart
rhythms or artificial heart valves; it is
also used to treat clots that form in
extremities such as legs, arms, or some-
times the lungs. Its anticoagulant
effect is acutely altered by even small
amounts of alcohol. In people taking
warfarin and ingesting a few drinks in
one sitting, anticlotting effects may be
stronger than necessary for medical
purposes, placing these people at risk
for increased bleeding. This excessive
warfarin activity results from alcohol-
related inhibition of warfarin metab-
olism by cytochrome P450 in the liver
(Lieber 1994). Conversely, in people
who chronically drink alcohol, long-
term alcohol consumption activates
cytochrome P450 and, consequently,
warfarin metabolism. As a result, war-
farin is broken down faster than nor-
mal, and higher warfarin doses are
required to achieve the desired antico-
agulant effect. Thus, alcohol con-
sumption can result in dangerously
high or insufficient warfarin activity,
depending on the patient’s drinking
pattern. Therefore, patients taking
warfarin generally should avoid alcohol.
Moderate Alcohol
Consumption and OTC 
or Herbal Medications
Use of OTC medications is widespread
among the general population. Accord-
ing to a recent survey, 85 percent of
adults ages 18 and older have used
OTC pain relievers at least once, and
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6Moderate alcohol use by itself, however, does not
appear to be associated with an increased risk of
ulcers or gastrointestinal bleeding and also is
unlikely to cause a certain type of inflammation
of the stomach lining (i.e., hemorrhagic gastritis)
that has been observed after heavy alcohol use.
up to 34 percent use OTC pain reliev-
ers on a weekly basis, often without
consulting a pharmacist. Furthermore,
a recent scientific panel convened by
the American Pharmaceutical Associa-
tion (1997) reported that although
adults frequently use OTC medica-
tions, many consumers fail to read the
product warning labels. Finally, con-
sumers frequently are unaware of the
type of medication they take (e.g.,
NSAID or analgesic). For example,
only one in three adults are familiar
with the product names acetaminophen,
aspirin, or ibuprofen and are able to
link these product names to specific
brand names. As a result, many con-
sumers are not fully aware of the
potential risks of taking these products,
particularly in combination with other
prescription medications or alcohol. 
Another factor contributing to an
increasing risk of medication-medica-
tion or alcohol-medication interac-
tions is that many medications that
previously were available only by pre-
scription (e.g., H2RAs and NSAIDs)
are gaining OTC status. OTC mar-
keting strategies, however, often lead
the consumer to think that these
medications are safe to use on an “as-
needed” basis, even though they can
be potentially dangerous when used
with alcohol. For example, the mes-
sage that “acid blocker” medications
can be used before or during a spicy
meal to prevent heartburn symptoms
may lead consumers to believe that
this practice is also acceptable when
they drink alcohol with their meal. 
Not only the combination of alcohol
and OTC products but also the amount
of alcohol contained in various OTC
products can be dangerous (see table 1).
Alcohol concentrations in these products
can be substantial; mouthwashes and
cough syrups tend to have the highest
alcohol contents. In an effort to control
the alcohol amounts in these products
and promote safety, the Food and
Drug Administration’s (FDA’s) OTC-
drugs advisory committee has adopted
the following limits on the amount of
alcohol considered appropriate: 
• For children under age 6, products
should be “alcohol free” (i.e., have
an alcohol content of 0.5 percent
or less).
• For children ages 6 to 12, the alco-
hol content should range between
0.5 and 5 percent.
• For people over age 12, the alcohol
content should not exceed 5 to 10
percent.
These levels represent only guide-
lines, however, and are not enforced
by the FDA. The manufacturers of
OTC products have agreed to main-
tain certain standards to keep their
products as close to these suggestions
as possible. Nevertheless, higher alco-
hol concentrations are considered
acceptable in certain products, such as
herbal medications, because alcohol
often is needed to extract and dissolve
organic substances from plants. 
Herbal medications currently are
widely used, and many people assume
that because these products are “natu-
ral,” they also are safe to use. This
assumption may not always be correct,
however. For example, chamomile,
echinacea, and valerian commonly are
used as sleep aids, and like prescrip-
tion and OTC products that cause
sedation, these herbal products may
produce enhanced sedative effects in
the CNS when combined with alco-
hol. In addition, liver toxicities caused
by various natural products have now
been identified (Heathcote and Wanless
1995), and their combination with
alcohol may enhance potential adverse
effects. To date, limited documentation
of such interactions exists because of a
lack of scientific studies on this subject
(Miller 1998).
Conclusions
Alcohol’s effects on the metabolism
and activities of various medications
have been well documented in chronic
heavy drinkers. The effects of moderate
alcohol consumption, however, have
not been studied as thoroughly. Those
effects most likely to be clinically sig-
nificant are the risk of over-sedation
resulting from the combination of
benzodiazepines and alcohol and the
interaction of alcohol with warfarin.
Given the variety and complexity of
observed interactions between alcohol
and numerous medications, it is diffi-
cult to recommend an alcohol con-
sumption level that can be considered
safe when taking medications. As a
rule, people taking either prescription
or OTC medications should always
read the product warning labels to
determine whether possible interactions
exist. Similarly, health care providers
should be alert to the potential for
moderate alcohol use to either enhance
medication effects or interfere with
the desired therapeutic actions of a
medication. 
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Many people who are being treated for chronichealth problems, such as diabetes and highblood pressure (i.e., hypertension), consume
alcohol, whether occasionally or regularly. As described
in the main article, alcohol consumption, even at mod-
erate levels, may interfere with the activities of many
medications prescribed for such conditions. In addi-
tion, however, alcohol use may contribute to or exac-
erbate certain medical conditions.
Diabetes
In people with diabetes, control of the levels of the
sugar glucose in the blood is severely impaired, either
because these people lack the hormone insulin, which
plays a central role in blood sugar regulation, or
because their body does not respond appropriately to
the insulin they produce. Alcohol consumption in dia-
betics can result either in higher-than-normal blood
sugar levels (i.e., hyperglycemia) or in lower-than-nor-
mal blood sugar levels (i.e., hypoglycemia), depending
on the patient’s nutritional status (Emanuele et al.
1998). Thus, long-term (i.e., chronic) alcohol consump-
tion in well-nourished diabetics can lead to hyper-
glycemia. Conversely, alcohol consumption in diabetics
who have not eaten for a while and whose glucose
resources are exhausted (i.e., who are in a fasting state)
can induce hypoglycemia. Both hyperglycemia and
hypoglycemia can have serious health consequences.
Diabetes medications that substitute for or stimulate
the body’s own insulin production (e.g., insulin or sul-
fonylureas) also may lead to hypoglycemia. 
Alcohol-induced hypoglycemia occurs in the fasted
state, when the diabetic’s blood sugar levels are already
low and the body depends on the production of new
glucose molecules (i.e., gluconeogenesis) to maintain
sufficient blood glucose levels. Gluconeogenesis,
which occurs in the liver, requires certain compounds
whose levels are regulated by a substance called reduced
nicotinamide adenine dinucleotide (NADH). Alcohol
metabolism in the liver generates excessive NADH
levels and thus reduces the levels of the compounds
needed for gluconeogenesis, thereby contributing to 
a further drop in blood sugar levels. This response is
particularly critical in diabetics taking medications
that can cause hypoglycemia. Consequently, these
patients should be advised to drink alcohol only with
or shortly after meals.
Diabetics who consume alcohol also must be alert
to the fact that the symptoms of mild intoxication
closely resemble those of hypoglycemia. Accordingly,
diabetics should check their blood glucose levels when-
ever they are uncertain about whether their symptoms
are caused by hypoglycemia or alcohol intoxication
(for additional recommendations for diabetics who
consume alcohol, see the textbox). Finally, patients
using certain diabetes medications (e.g., chlorpropamide)
should be cautioned that the medications can cause a
disulfiram-like reaction when alcohol is consumed.
Hyperlipidemia
In people with hyperlipidemia, the levels of fat
molecules in the blood—particularly molecules called
triglycerides—are higher than normal. This condition
can be associated with an increased risk of various health
problems, the most serious of which is cardiovascular
disease. Alcohol consumption may exacerbate hyper-
lipidemia, because the same metabolic alcohol effects
that inhibit gluconeogenesis also inhibit fat metabolism.
As a result, the production of certain molecules called
very low density lipoprotein (VLDL) particles is
increased. Thus, people with elevated triglyceride lev-
els in the blood should probably abstain from alcohol
to determine if alcohol consumption is contributing
to their elevated lipid levels.
Hypertension
Elevated blood pressure is a risk factor for cardiovas-
cular disease, including heart attacks. Alcohol is
known to cause a dose-dependent elevation in blood
pressure (Beilin 1995). Researchers do not yet know
exactly what levels of alcohol consumption cause
hypertension (for more information, see the article
by Klatsky, pp. 15–23). However, all patients who
Alcohol’s Influences on 
Various Disease States
What Is Moderate Drinking?
Vol. 23, No. 1, 1999 53
Alcohol and Medication Inte act ons
are diagnosed with high blood pressure should be
questioned regarding their alcohol intake before
being started on antihypertensive therapy. In some
of those patients, cessation of drinking alone may
reduce blood pressure and thus obviate the need for
pharmacological treatment. Furthermore, patients
taking certain kinds of cardiac  medications (e.g.,
isosorbide [Isordil and Ismo], terazosin [Hytrin],
doxazosin [Cardura]) should be warned that alco-
hol consumption in combination with those medi-
cations may cause lower-than-normal blood pres-
sure. These important potential risks associated
with even moderate alcohol consumption (i.e., one
or two standard drinks1 per day) must be consid-
ered when discussing the cardiovascular benefits
associated with moderate drinking (e.g., reduced
risk of heart attacks and certain kinds of strokes.)
Hepatitis C Infection
Infection with the hepatitis C virus, which can result
in serious and even fatal liver damage, is common in
the United States and around the world. The only
effective treatment to date involves a substance called
interferon-α, often in combination with an agent
called ribavirin, and has a cure rate of approximately
40 percent. Heavy alcohol use in patients infected
with hepatitis C accelerates the rate of liver damage
and increases the risk of cirrhosis. Moreover, heavy
alcohol use appears to reduce the number of hepati-
tis C-infected people who respond to treatment with
interferon-α. Researchers do not yet know how 
alcohol consumption exacerbates disease progression
and interferes with treatment. Nevertheless, people
infected with the hepatitis C virus probably should
avoid using alcohol, particularly during interferon-α
treatment. 
—Ron Weathermon and David W. Crabb
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Preventing Alcohol-Induced
Hypoglycemia
Alcohol-consuming diabetic patients should 
consider the following general suggestions
for preventing alcohol-induced hypoglycemia:
• Never consume alcohol without food 
or while in a fasting state.
• Consume only moderate amounts of 
alcohol (i.e., one or two bottles of beer,
glasses of wine, or mixed drinks at one
sitting), and drink no more than once 
or twice weekly.
• Allow 1.5 to 2 hours between drinks.
• Avoid sugar-containing drinks, and
consume only light beer, dry wine, or
drinks mixed with diet sodas.
• Check blood sugar levels if unsure 
whether certain body sensations (e.g.,
light-headedness) result from hypo-
glycemia or alcohol effects.
• Be on the alert for alcohol hidden in 
prescription and over-the-counter 
medications.
1A standard drink is defined as one 12-ounce can of beer or bottle of
wine cooler, one 5-ounce glass of wine, or 1.5 ounces of distilled spirits
and is equivalent to approximately 0.5 ounce, or 12 grams (g), of pure
alcohol.
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 Mothers Against Drunk Driving
September 16–19
Albuquerque, NM
 American Society of 
Human Genetics 
October 19–23
San Francisco, CA
 Association of American 
Medical Colleges
October 22–28
Washington, DC
 Society for Neuroscience 
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Miami Beach, FL
 National Association of Social Workers
East Region Meeting
October 29-30
New Orleans, LA
 American Public Health Association
November 7–11
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Visit NIAAA in 1999!
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites you to visit its
scientific exhibit at upcoming conferences around the country. 
1999 Conferences
The Alcohol and Alcohol Problems Science Database (ETOH), recent NIAAA
publications, and research grant information will be on display.
